What is HC Wainwright’s Estimate for AVXL Q2 Earnings?

Anavex Life Sciences Corp. (NASDAQ:AVXL) – HC Wainwright raised their Q2 2026 earnings per share estimates for shares of Anavex Life Sciences in a note issued to investors on Tuesday, February 10th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.33) EPS.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04.

Other analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 target price on shares of Anavex Life Sciences in a research note on Monday. Finally, Jones Trading downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 24th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $22.00.

Anavex Life Sciences Trading Down 2.0%

Anavex Life Sciences stock opened at $3.88 on Thursday. Anavex Life Sciences has a 12-month low of $2.86 and a 12-month high of $13.99. The firm has a 50-day moving average price of $4.28 and a 200-day moving average price of $6.95. The firm has a market capitalization of $359.56 million, a PE ratio of -8.43 and a beta of 1.21.

Institutional Trading of Anavex Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. State of Wyoming bought a new position in Anavex Life Sciences in the second quarter worth approximately $26,000. AlphaQuest LLC purchased a new stake in shares of Anavex Life Sciences in the 3rd quarter worth $29,000. Quarry LP purchased a new stake in shares of Anavex Life Sciences in the 3rd quarter worth $36,000. SBI Securities Co. Ltd. grew its position in shares of Anavex Life Sciences by 470.0% during the 2nd quarter. SBI Securities Co. Ltd. now owns 4,879 shares of the biotechnology company’s stock worth $45,000 after buying an additional 4,023 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Anavex Life Sciences by 11,540.0% during the third quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 6,924 shares during the period. Institutional investors own 31.55% of the company’s stock.

Trending Headlines about Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $20.00 price target (implying large upside) and published FY2027 and quarterly EPS forecasts that are less negative than consensus (FY2027 -$0.55 vs consensus -$0.69) — supportive for sentiment and valuation expectations. MarketBeat – AVXL HC Wainwright Report
• Positive Sentiment: Analysis pieces argue Anavex may be approaching cash‑flow breakeven, a narrative investors view positively for a small biotech with ongoing R&D spend. Breakeven On The Horizon For Anavex Life Sciences (Yahoo)
• Neutral Sentiment: The company’s Q1 2026 earnings call transcript is available for investors wanting primary detail on recent results and management commentary; it may clarify near‑term guidance but contains no single market‑moving surprise. Q1 2026 Earnings Call Transcript (MSN)
• Neutral Sentiment: Short‑interest reports show 0 shares and a days‑to‑cover of 0.0, but entries include NaN and appear to be data glitches — there is no clear evidence of new short pressure driving the move. (No linked source; reported in market data feed.)
• Negative Sentiment: A Seeking Alpha piece highlights a negative European regulator opinion on blarcamesine, Anavex’s lead asset, calling the program into “regulatory purgatory” — that regulatory uncertainty is the most direct near‑term negative for valuation and explains downward pressure. Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory (Seeking Alpha)

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.